David Dai
Stock Analyst at Bernstein
(3.07)
# 3,069
Out of 5,182 analysts
39
Total ratings
48.48%
Success rate
1.58%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASML ASML Holding | Maintains: Outperform | $1,911 → $1,971 | $1,478.28 | +33.33% | 3 | Mar 26, 2026 | |
| JSPR Jasper Therapeutics | Assumes: Neutral | $1.5 | $0.80 | +86.96% | 1 | Mar 23, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $7 → $8 | $4.47 | +78.97% | 3 | Mar 18, 2026 | |
| SONY Sony Group | Downgrades: Market Perform | $30 → $22 | $21.05 | +4.51% | 2 | Mar 17, 2026 | |
| KURA Kura Oncology | Maintains: Buy | $16 → $15 | $8.67 | +73.01% | 4 | Mar 13, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $2 → $4 | $3.70 | +8.11% | 3 | Mar 5, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $90 → $128 | $85.05 | +50.50% | 1 | Mar 3, 2026 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $95.50 | +22.51% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $24.44 | +55.48% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $102.74 | +28.48% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $20 | $10.54 | +89.75% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $26 | $16.03 | +62.20% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $19.67 | +52.52% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $14.54 | +65.06% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $31.05 | -22.71% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $14.93 | +362.16% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $30.50 | +63.93% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $67.70 | -11.37% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $6.76 | +6,527.22% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $75.27 | -46.86% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $3.60 | +1,011.11% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.17 | +2,204.15% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $28.93 | +79.74% | 1 | Mar 17, 2020 |
ASML Holding
Mar 26, 2026
Maintains: Outperform
Price Target: $1,911 → $1,971
Current: $1,478.28
Upside: +33.33%
Jasper Therapeutics
Mar 23, 2026
Assumes: Neutral
Price Target: $1.5
Current: $0.80
Upside: +86.96%
Perspective Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $7 → $8
Current: $4.47
Upside: +78.97%
Sony Group
Mar 17, 2026
Downgrades: Market Perform
Price Target: $30 → $22
Current: $21.05
Upside: +4.51%
Kura Oncology
Mar 13, 2026
Maintains: Buy
Price Target: $16 → $15
Current: $8.67
Upside: +73.01%
Iovance Biotherapeutics
Mar 5, 2026
Maintains: Neutral
Price Target: $2 → $4
Current: $3.70
Upside: +8.11%
Kymera Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $90 → $128
Current: $85.05
Upside: +50.50%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $95.50
Upside: +22.51%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $24.44
Upside: +55.48%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $102.74
Upside: +28.48%
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $10.54
Upside: +89.75%
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $16.03
Upside: +62.20%
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $19.67
Upside: +52.52%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $14.54
Upside: +65.06%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $31.05
Upside: -22.71%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $14.93
Upside: +362.16%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $30.50
Upside: +63.93%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $67.70
Upside: -11.37%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $6.76
Upside: +6,527.22%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $75.27
Upside: -46.86%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $3.60
Upside: +1,011.11%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.17
Upside: +2,204.15%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $28.93
Upside: +79.74%